WILMINGTON, DE — Incyte (Nasdaq: INCY) reported 54-week Phase III data showing its experimental drug povorcitinib reduced disease activity in patients with moderate to severe hidradenitis suppurativa, the company announced at the American Academy of Dermatology Annual Meeting.
The results from the STOP-HS1 and STOP-HS2 trials showed reductions in inflammatory lesions and symptom severity compared with baseline in patients receiving povorcitinib alongside standard care.
The company said up to 71.4% of patients achieved a 50% reduction in abscesses and inflammatory nodules, while up to 57% achieved a 75% reduction and up to 29% achieved complete response at Week 54.
The trials enrolled approximately 2,306 adult patients with a history of moderate to severe disease who continued to experience symptoms despite prior treatment.
Participants initially received povorcitinib or placebo during a 12-week period, followed by a 42-week extension in which all patients received the drug.
The company said treatment led to reductions across key lesion types, including abscesses, nodules and draining tunnels, with complete clearance achieved in up to 20% of patients.
Patients also reported improvements in symptoms such as skin pain and fatigue, as well as overall quality of life measures, according to the data.
Pablo J. Cagnoni, president and head of research and development at Incyte, said the findings support the drug’s potential as a treatment option.
“Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success,” Cagnoni said.
The safety profile over 54 weeks was consistent with earlier data, with most adverse events reported as mild or moderate, the company said.
Treatment-emergent adverse events occurred in 76.2% to 83.4% of patients, while serious adverse events were reported in 3.7% to 6.4% of participants.
The company said regulatory applications for povorcitinib in hidradenitis suppurativa are under review by the U.S. Food and Drug Administration and the European Medicines Agency.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.